Double-blind, Placebo-controlled, Randomized, Ascending Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LGD-6972 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

Trial Profile

Double-blind, Placebo-controlled, Randomized, Ascending Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LGD-6972 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs LGD 6972 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Ligand Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2016 According to Ligand Pharmaceuticals Median Release results of two phase I stuidies (phase Ia and phase Ib) were published in the Journal of Diabetes, Obesity and Metabolism.
    • 15 Aug 2016 Results published in the Ligand Pharmaceuticals Media Release
    • 08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top